Atossa Therapeutics (NASDAQ:ATOS) Issues Earnings Results

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) announced its quarterly earnings data on Monday. The company reported ($0.06) earnings per share for the quarter, Yahoo Finance reports.

Atossa Therapeutics Trading Down 8.0 %

Shares of ATOS opened at $1.84 on Wednesday. The firm has a market cap of $230.55 million, a PE ratio of -7.67 and a beta of 1.19. The firm has a fifty day simple moving average of $1.17 and a two-hundred day simple moving average of $0.90. Atossa Therapeutics has a 1-year low of $0.59 and a 1-year high of $2.11.

Institutional Investors Weigh In On Atossa Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its stake in shares of Atossa Therapeutics by 10.8% in the 1st quarter. Renaissance Technologies LLC now owns 936,070 shares of the company’s stock worth $679,000 after purchasing an additional 91,300 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Atossa Therapeutics by 29.3% in the fourth quarter. GSA Capital Partners LLP now owns 449,082 shares of the company’s stock worth $395,000 after purchasing an additional 101,690 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Atossa Therapeutics by 4.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 313,912 shares of the company’s stock worth $393,000 after purchasing an additional 14,481 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of Atossa Therapeutics during the 2nd quarter valued at $365,000. Finally, Northern Trust Corp raised its position in shares of Atossa Therapeutics by 6.2% during the 4th quarter. Northern Trust Corp now owns 227,922 shares of the company’s stock valued at $201,000 after purchasing an additional 13,280 shares during the period. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on ATOS. Cantor Fitzgerald restated an “overweight” rating on shares of Atossa Therapeutics in a report on Friday, January 12th. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Atossa Therapeutics in a report on Tuesday. Finally, StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 18th.

Check Out Our Latest Stock Analysis on Atossa Therapeutics

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Featured Stories

Earnings History for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.